Key features of patient demographics and baseline data for selected studies
| csDMARD-IR | |
| Patient demographics | |
| Age | Mean ages were similar between all studies (and study arms) ranging from 46.7 years35 to 57.3 years36–38 |
| Sex | In all trials except ATTEST, the majority of patients were female |
| Ethnicity | In those trials reporting ethnicity, the majority of the patients were Caucasian, although in seven trials, the entire population was Asian35 39–45 |
| Patient baseline clinical status | |
| Weight | Mean weight ranged from 52.9 kg (J-RAPID) to 82 kg (MEASURE) |
| Proportion rheumatoid factor positive | The proportion of patients who were rheumatoid factor positive was above 60% in all studies reporting this value, except for the ASSET trial (55.6% for abatacept intravenous 8 mg/kg q4w+methotrexate) |
| Disease duration | Mean disease duration ranged widely, from 6 months (SWEFOT) to 13.1 years (ARMADA) |
| Tender joint count | Mean tender joint count ranged from 3 (ENCOURAGE) to 35 (DANCER) on the 68-count scale |
| Swollen joint count | Mean swollen joint count ranged from 3.2 (CERTAIN) to 24.0 (ATTRACT) on the 66-count scale |
| Prior DMARD use | Prior DMARD use ranged from 1.1 (STAR) to 3.1 (ARMADA) in 26 studies that reported prior DMARD use |